World-first clinical trials begin for promising new anti-clotting stroke drug - Sunrise on 7

Leading scientists at the Heart Research Institute (HRI) have made a breakthrough 25 years in the making, identifying and developing a new anti-clotting drug that shows great promise in the treatment of stroke, with Phase II clinical trials about to start. To read more about this story, visit HRI's website: www.hri.org.au/news/world-first-clinical-trials-begin-for-promising-new-anti-clotting-stroke-drug
HRI is an internationally recognised medical research institute that performs groundbreaking cardiovascular research. HRI’s mission is to prevent death and suffering from cardiovascular diseases, a complex array of diseases affecting the heart and blood vessels.
We will address areas of unmet need in cardiovascular diseases including coronary artery disease, stroke, peripheral artery disease, hypertension, heart failure, preeclampsia, congenital heart disease and pulmonary vascular disease, as well as metabolic complications such as diabetes.
Subscribe to HRI’s newsletter: www.hri.org.au...
Head to HRI’s website: www.hri.org.au
Follow HRI on Twitter: / hriaust
Follow HRI on LinkedIn: www.linkedin.com/company/heart-research-institute
Follow HRI on Facebook: HRIAust